Author:
Fravel Michelle A.,Meaney Calvin J.,Noureddine Lama
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. MacLaughlin EJ, Saseen JJ. Hypertension. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey L. eds. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition. McGraw Hill; 2023. Accessed August 01, 2023.
https://accesspharmacy.mhmedical.com/content.aspx?bookid=3097§ionid=267225CiteReference.439.
2. •• GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63. This landmark trial established efficacy of RAAS inhibitor therapy in CKD.
3. •• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9. This landmark trial established efficacy of RAASi therapy in CKD.
4. •• Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8. This landmark trial established efficacy of RAASi therapy in CKD.
5. Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, et al. STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021–2032.